Tissue Inhibitor of Metalloproteinase-2 Polymorphisms and Risk for HIV-Associated Neurocognitive Disorder
Table 3
Frequency distribution of TIMP-2 (-418G/C and 303G/A) polymorphisms in HIV patients without HAND and healthy controls.
Genotypes TIMP-2 -418G/C
Patients without HAND () (%)
Healthy controls () (%)
value
OR (95% CI)
GG
67 (67.0%)
118 (76.6%)
1
Reference
GC
20 (20.0%)
34 (22.1%)
0.92
1.04 (0.52-2.08)
CC
13 (13.0%)
2 (1.3%)
0.006
10.10 (1.97-51.68)
Alleles TIMP-2 -418G/C
Patients without HAND () (%)
Healthy controls () (%)
value
OR (95% CI)
G
154 (77.0%)
270 (87.7%)
1
Reference
C
46 (23.0%)
38 (12.3%)
0.009
2.02 (1.20-3.41)
Genotypes TIMP-2 303G/A
Patients without HAND (N=100) (%)
Healthy controls () (%)
value
OR (95% CI)
GG
71 (71.0%)
106 (68.8%)
1
Reference
GA
28 (28.0%)
45 (29.2%)
0.97
1.01 (0.54-1.89)
AA
1 (1.0%)
3 (1.9%)
0.42
0.34 (0.025-4.66)
Alleles TIMP-2 303G/A
Patients without HAND ()
Healthy controls () (%)
value
OR (95% CI)
G
170 (85.0%)
257 (83.4%)
1
Reference
A
30 (15.0%)
51 (16.6%)
0.54
0.84 (0.49-1.46)
= total number of subjects, (%) = frequency of genotypes/alleles; age-adjusted OR (odds ratios) and 95% CI (confidence intervals) were derived from logistic regression models comparing the homozygous wild-type genotype/allele (GG genotype and G allele for TIMP-2 -418G/C and 303G/A were taken as reference) with other genotypes/alleles. Significant values () and related OR (95% CI) have been shown in bold.
